- Previous Close
8.91 - Open
9.10 - Bid --
- Ask 7.99 x 100
- Day's Range
7.69 - 9.10 - 52 Week Range
6.10 - 25.00 - Volume
61,709 - Avg. Volume
61,614 - Market Cap (intraday)
149.03M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.63 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NeOnc Technologies Holdings, Inc., a clinical-stage life sciences company, focuses on the development and commercialization of central nervous system therapeutics designed to overcome the blood-brain barrier. The company's NEO drug development platform produces a portfolio of novel drug candidates and delivery methods with patent protections. Its NEO100-01 and NEO100-02 therapeutics are in Phase II, and the NEO100-03 and NEO212 therapeutics are in Phase I clinical trials, advancing under FDA Fast-Track and Investigational New Drug status. NeOnc Technologies Holdings, Inc. was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was founded in 2008 and is based in Westlake Village, California.
www.neonctech.comRecent News: NTHI
View More
Performance Overview: NTHI
Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NTHI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NTHI
View MoreValuation Measures
Market Cap
149.03M
Enterprise Value
148.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.80k
Price/Book (mrq)
--
Enterprise Value/Revenue
1.80k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-189.57%
Return on Equity (ttm)
--
Revenue (ttm)
83k
Net Income Avi to Common (ttm)
-11.9M
Diluted EPS (ttm)
-0.63
Balance Sheet and Cash Flow
Total Cash (mrq)
64.89k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.12M